Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439868 · ClinicalTrials.gov registry record · Phase 1
A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure
A Phase 1 study of Depressive Disorder, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00439868: Completed Phase 1 study of Depressive Disorder, sponsored by GlaxoSmithKline.
NCT00439868 is a Phase 1 study of Depressive Disorder that has completed, run by GlaxoSmithKline. The registered enrollment target is 33 participants, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00439868, a Phase 1 study of Depressive Disorder, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.
Conditions Studied
Interventions
- DRUG placebo
- DRUG WellbutrinXL
Study Locations (1)
Florida
- GSK Investigational Site - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-02-16 |
| Est. Completion | 2007-06-08 |
| Phase | Phase 1 |
What the finished NCT00439868 record still lists
NCT00439868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00439868 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00439868 about?
NCT00439868 is a clinical study titled "A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure". This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.
What is the current status of trial NCT00439868?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2007-02-16. Estimated completion is 2007-06-08.
What conditions does trial NCT00439868 study?
This clinical trial studies the following conditions: Depressive Disorder.
What interventions are being tested in trial NCT00439868?
The interventions under investigation include: placebo (DRUG), WellbutrinXL (DRUG).
Who is sponsoring clinical trial NCT00439868?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00439868 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00439868's enrollment target sits among peer trials
33 42nd of 47 higher than 6 of 47 other Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Therapist Behavior on the Treatment of Depressed Adolescents
COMPLETED · Phase 1
-
Effect of Nicotine on Brain Reward Pathways
COMPLETED · Phase 1
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
Measurement-Based Care (MBC) Implementation, Effectiveness, and Mechanisms of Change
RECRUITING · NA
-
Research Evaluating Vagal Excitation AND Anatomical Links
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI